Welcome to our dedicated page for Integrated Biopharma SEC filings (Ticker: INBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integrated BioPharma, Inc. (INBP) files a range of documents with the U.S. Securities and Exchange Commission that provide insight into its business of manufacturing, distributing, marketing and selling vitamins, nutritional supplements and herbal products. These SEC filings include current reports on Form 8-K, annual reports on Form 10-K referenced in proxy materials, and definitive proxy statements on Schedule 14A.
For INBP, Form 8-K filings frequently report financial results for specific quarters and fiscal years under Item 2.02 (Results of Operations and Financial Condition). These filings typically furnish an earnings press release as an exhibit, summarizing revenue, operating income or loss, net income or loss and related per-share data, along with commentary on revenue concentration in the Contract Manufacturing Segment and performance of the nutraceutical business.
The company’s definitive proxy statement (DEF 14A) describes corporate governance and stockholder voting matters, including the election of a Class III director for a three-year term, advisory votes on executive compensation and the frequency of such votes, and ratification of the independent auditor for a specified fiscal year. It also explains record dates, voting procedures and quorum requirements for the annual meeting of stockholders.
Form 8-K filings related to the annual meeting disclose final voting results for director elections, advisory compensation proposals, advisory frequency of vote on executive compensation and auditor ratification. Together, these filings allow investors to review Integrated BioPharma’s financial reporting, governance structure and stockholder decisions.
On this page, SEC filings for INBP are updated from EDGAR as they become available. AI-powered tools can help summarize lengthy documents, highlight key items such as revenue trends, customer concentration in the Contract Manufacturing Segment, and outcomes of stockholder votes, and make it easier to interpret the implications of the company’s 10-K, 8-K and proxy disclosures.
Integrated BioPharma Inc. saw a long‑standing shareholder group led by the late Carl DeSantis, CD Financial, LLC and CDS Group Holdings, L.L.C. report that it no longer beneficially owns any common stock. The filing states the group’s holdings fell to 0 shares, or 0.0% of the class.
Following DeSantis’s death, all of the group’s shares were transferred on March 24, March 30 and April 15, 2026 to CDDS 2.0, LLC, a Florida company controlled by Damon DeSantis. As a result, CDDS 2.0, LLC directly, and Damon DeSantis indirectly, now beneficially own more than five percent of Integrated BioPharma’s common stock.
Integrated BioPharma Inc. received an updated ownership report showing concentrated control of its common stock. CDDS 2.0, LLC now holds 12,733,058 shares, about 41.0% of the company’s 31,059,610 outstanding shares as of April 15, 2026. Damon DeSantis is deemed to beneficially own 12,920,558 shares, or 41.3%, through CDDS and 187,500 presently exercisable stock options held directly. These positions arose from internal transfers from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis to CDDS for no cash consideration. The reporting group states it currently has no plans involving mergers, asset sales, control changes, or other actions listed in Item 4, while reserving the right to change its intentions.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported bona fide gifts of 11,201,964 shares of Common Stock. The transactions were coded as gifts at $0.0000 per share, indicating non-cash transfers.
The filing notes that 8,966,547 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis, and 2,235,417 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC. Following these transfers, associated indirect holdings total 2,374,084 shares and Milmoe directly owns 138,667 shares.
INTEGRATED BIOPHARMA INC director William H. Milmoe reported large stock gifts involving entities he is associated with. On April 15, 2026, entities linked to him made bona fide gifts totaling 11,201,964 shares of Common Stock at a stated price of $0.00 per share.
One gift transferred 8,966,547 shares from CD Financial, LLC to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. Another transferred 2,235,417 shares from the Carl DeSantis Revocable Trust to the same CDDS 2.0, LLC. After these gifts, Milmoe’s reported holdings were 2,374,084 shares indirectly and 138,667 shares directly of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC major shareholder Carl DeSantis reported estate-related gift transfers of 11,201,964 shares of Common Stock. Two bona fide gifts on April 15, 2026 disposed of 8,966,547 shares held by CD Financial, LLC and 2,235,417 shares held by the Carl DeSantis Revocable Trust.
According to the footnotes, both blocks were transferred to CDDS 2.0, LLC, a Florida limited liability company controlled by Damon DeSantis. The reporting person is noted as deceased, and these are indirect holdings. After the second transfer, the filing shows 0 shares of Common Stock indirectly owned.
Integrated BioPharma director and 10% owner Damon DeSantis reported two bona fide gift transfers of Common Stock involving related entities. The filing shows gifts of 8,966,547 and 2,235,417 shares, for a total of 11,201,964 shares, at a stated price of $0 per share.
According to the footnotes, these shares were transferred from CD Financial, LLC and the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, a Florida limited liability company controlled by DeSantis. After these transfers, DeSantis indirectly holds 12,733,058 shares of Integrated BioPharma Common Stock through CDDS 2.0, LLC.
Integrated BioPharma, Inc. reported that PNC Bank extended the expiration date of its line of credit, documented in an April 15, 2025 promissory note, from April 15, 2026 to July 14, 2026. The extension, which also covers subsidiary Manhattan Drug Company, Inc., becomes effective on April 16, 2026.
INTEGRATED BIOPHARMA INC insider reporting reflects non-market gifts of Common Stock by entities associated with the late Carl DeSantis. CD Financial, LLC transferred 1,356,293 shares and the Carl DeSantis Revocable Trust transferred 7,392 shares to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. After these bona fide gifts, a total of 11,366,673 shares of Common Stock remain indirectly held through CD Financial, LLC, the revocable trust and the Estate of Carl DeSantis.
Integrated BioPharma director and 10% owner William H. Milmoe reported two bona fide gifts of Common Stock made through entities he is associated with. On March 24, 2026, 1,356,293 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, and 7,392 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC controlled by Damon DeSantis. These are non-cash, indirect transfers rather than market sales. After the gifts, Milmoe’s reported holdings across CD Financial, the revocable trust, the Estate of Carl DeSantis, and his direct ownership total 11,505,340 shares of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC director Damon DeSantis reported bona fide gift transfers involving 1,363,685 shares of Common Stock. The transactions, coded as gifts, were recorded at a price of $0.00 per share and are held indirectly through CDDS 2.0, LLC.
Footnotes state that 1,356,293 shares were transferred from CD Financial, LLC and 7,392 shares from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, which is controlled by DeSantis. Following these transfers, he indirectly holds 1,363,685 shares of the company’s common stock.